Cargando…
Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
BACKGROUND: Clinical trials in China have demonstrated that ranibizumab can improve the clinical outcomes of branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). However, no economic evaluation of ranibizumab has been conducted among Chinese patient population. METHODS: To...
Autores principales: | Ni, Weiyi, Liu, Jia, Jiang, Yawen, Wu, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142632/ https://www.ncbi.nlm.nih.gov/pubmed/34024275 http://dx.doi.org/10.1186/s12886-021-01997-1 |
Ejemplares similares
-
Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
por: Gerding, Heinrich, et al.
Publicado: (2015) -
Disease-modifying effects of ranibizumab for central retinal vein occlusion
por: Huang, Jason M., et al.
Publicado: (2021) -
The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries
por: Wu, Annie M., et al.
Publicado: (2018) -
Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
por: Goel, Siddhi, et al.
Publicado: (2019) -
Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
por: Dogan, Emine, et al.
Publicado: (2018)